Predictive biomarker for liver cancer associated with survival outcomes, effectiveness of systemic therapy

Medical Xpress - latest medical and health news stories ·
Health & Medicine United Kingdom

Liver cancer was the sixth most common cancer and the third leading cause of cancer-related deaths worldwide in 2022, with hepatocellular carcinoma (HCC) as the most common histological subtype, accounting for approximately 90% of liver cancers. Despite this, biomarkers that predict survival and therapeutic response to atezolizumab plus bevacizumab (Atezo/Bev), a type of systemic therapy in HCC…

Read original article on Medical Xpress - latest medical and health news stories →